ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat
ResMed Analyst Backs Portfolio Reset
ResMed to sell software business MatrixCare for $490 million
This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday